奥赛康10月17日早间公告，公司的控股子公司AskGene Pharma与Visara达成授权许可协议，将AskGene Pharma具有自主知识产权的1类创新药ASKG712项目在许可区域内的权益有偿许可给Visara。ASKG712 临床用于治疗眼底黄斑疾病，目前处于中国IIa期临床研究阶段。根据许可协议，许可区域为大中华地 区、新加坡、泰国、马来西亚、印度尼西亚、越南、韩国及印度，Visara将获得ASKG712项目在许可区 域内开发、生产和商业化的独家权利。Visara将向AskGene Pharma支付700万美元首付款，AskGene Pharma有权收取与研发、注册及商业化相关的里程碑付款，最高不超过8900万美元。AskGene Pharma 有权根据产品在许可区域内的年度净销售额收取一定比例的特许权使用费。 ...

Core Viewpoint - Heng Rui Medicine has entered into an agreement with Braveheart Bio to license its innovative drug HRS-1893 for a total of $75 million, with potential milestone payments reaching up to $1.013 billion based on clinical development and sales performance [1][2]. Group 1: Agreement Details - Heng Rui Medicine will grant Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]. - Braveheart Bio will pay an upfront fee of $65 million, consisting of $32.5 million in cash and $32.5 million in equity, along with a $10 million milestone payment upon completion of technology transfer, totaling $75 million [1]. - Heng Rui Medicine is eligible for additional milestone payments related to clinical development and sales, which could reach up to $1.013 billion [1]. Group 2: Drug Information - HRS-1893 is a myosin selective inhibitor that works by inhibiting the ATPase activity of cardiac myosin, thereby reducing excessive contraction of the myocardium, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2]. - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2].

Group 1 - Company Heng Rui Medicine (600276.SH) has entered into an agreement with Braveheart Bio, Inc. to license its innovative drug HRS-1893, which has independent intellectual property rights [1] - The licensing agreement grants Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million to Heng Rui, which includes a $65 million upfront payment and a $10 million milestone payment upon completion of technology transfer [1] Group 2 - HRS-1893 is a myosin selective inhibitor that works by inhibiting the activity of cardiac myosin ATPase, thereby reducing excessive myocardial contraction, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2] - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2]